HomeBUSINESS
BUSINESS

Pfizer Wringing Hands over PMP Eligibility for Lorlatinib; It Might Earn 1st Conditional OK, but It’s “4th” ALK Inhibitor
(Jul.5.2018)

Will Pfizer Japan’s next-generation ALK inhibitor lorlatinib qualify for the price maintenance premium (PMP) scheme for innovative medicines? The drug might bag the country’s first conditional drug approval as early as this autumn, but its fourth-in-class status in the ALK space is casting a cloud over its future PMP eligibility ...
(LOG IN FOR FULL STORY)

News Calendar